Everything can be going wrong, but late stage analysis can save the day for your new treatment.
Previously, we discussed how the Phase Three clinical trials and approvals process is significantly more difficult than the first two combined. Late stage analysis can save the day for many organizations. Read more
When it comes to selecting a biostatistical CRO, most sponsors choose to work with the cheapest proposal. But that’s a mistake and your organization will pay dearly for it in the long run. Not only does the lowest bid frequently come with a number of hidden costs and overages, there’s also the small matter of accuracy — and compliance. Accuracy, in the final analysis, should be the ultimate factor when deciding which CRO will conduct your biostatistical research. To use any other criteria is to gamble with your organization’s future. Read more